Pharmaceutical market of Russia

Development of the medical and pharmaceutical industry (state program)

Main article: Development of medical and pharmaceutical industry (state program)

Selling drugs on the Internet in Russia

Main article: Sale of medicines on the Internet in Russia

Import substitution of drugs

Main article: Import substitution of drugs in Russia

Pharmaceutical market of Moscow

Main article: Pharmaceutical market in Moscow

Production of drugs and medical devices in Moscow

Main article: Production of drugs and medical devices in Moscow

Counterfeit medicines

Main article: Counterfeit medicines

2023

Imports of drugs to Russia for the year decreased by 13.75% to ₽2,2 trillion

The volume of the Russian pharmaceutical market in 2023 amounted to ₽2 328 trillion, which is 4% more than in 2022 (₽2,2 trillion). This follows from the data provided by the Ministry of Industry and Trade of Russia in August 2024. However, drug imports during this period decreased by 13.75%, to $13.8 billion against $16 billion a year earlier in 2022.

According to Dmitry Galkin, Director of the Department for the Development of the Pharmaceutical and Medical Industry of the Ministry of Industry and Trade of Russia, despite the reduction in imports, this indicator still exceeds the levels of 2020 ($10.6 billion) and 2021 ($13.5 billion). According to him, the share of domestic drugs in the Russian market in value terms reached 36.8%, and in kind - 62.9%.

According to GxPnews, in accordance with the Register of Licenses as of August 1, 2024, 553 local manufacturers of medicines were registered in Russia. At the same time, the State Register of Medicines (GRLS) of the Ministry of Health lists 21,193 marketing authorizations, of which 14,422 are with the possibility of issuing a finished dosage form in the Russian Federation or manufacturing in a full cycle.

Also, according to the Ministry of Industry and Trade, the List of Vital and Essential Drugs (VED) for August 2024 contains 819 items, 95% of which have production stages in Russia, including 58.4% in the full cycle and 19.2% from the stage of the finished dosage form. At the same time, the share of domestic drugs in the value of public procurement in 2023 amounted to 31.4%, and in kind - 81.7%.

The demand in the pharmaceutical market is changing, which leads to changes in the competitive environment, said Nikolai Bespalov, Development Director of RNC Pharma. According to him, some foreign manufacturers are withdrawing their drugs from the market due to the emergence of a large number of more affordable analogues, which are gaining popularity due to low prices.^[1]

Hydrogen peroxide production in Russia for 4 years increased by 9%

In 2023, approximately 113 thousand tons of hydrogen peroxide were produced in Russia. This is 4% more compared to the previous year, when the volume of output was estimated at 109 thousand tons. BusinesStat cites such data in a report submitted on March 27, 2024. Read more here.

Supplies of foreign activated coal to Russia have ceased to grow

In 2023, approximately 24.2 thousand tons of foreign activated carbon were imported into Russia. The volume of imports practically did not change compared to the previous year, when the figure was 24.3 thousand tons. That is, a decline of 0.6% was recorded, as reported in the materials of BusinesStat, published on March 22, 2024. Read more here.

Reduction of biopharmaceutical market volume for 2 years by 53% to RUB 131.5 bln

In 2023, the turnover of the biopharmaceutical market in Russia amounted to about 131.5 billion rubles. This is 8.1% less compared to the previous year and 53.1% less compared to 2021, when sales were estimated at 143.1 billion rubles and 280.5 billion rubles, respectively. Such data are provided in the BusinesStat report, published on March 26, 2024.

The study analyzes the market turnover of biopharmaceuticals and biotechnology for medicine in the Russian Federation. In particular, such products as antibiotics and bacteriophages, hormones (insulins, sex hormones, somatropin), protein kinase inhibitors, coagulants (including blood clotting factors), monoclonal antibodies, cytokines (interferons, erythropoietins), etc. are considered.

According to estimates, in 2019 the volume of the corresponding market amounted to 109.8 billion rubles. In 2020, an increase of 17.3% was noted - to 128.8 billion rubles, and in 2021, against the background of the COVID-19 pandemic, turnover soared on an annualized basis by 117.7%, reaching 280.5 billion rubles. The key factors in such a rapid increase in revenue were the development and release of vaccines against coronavirus. In addition, the market developed due to the production of biosimilars - copies of original drugs.

In 2022, a decline of 49% followed with a final result of 143.1 billion rubles. This is due to the normalization of the epidemic situation and a decrease in vaccination against coronavirus. In April 2023, the supply of vaccines against coronavirus at the expense of the federal budget stopped, as a result of which vaccination in a number of regions was suspended or carried out at a fee. At the same time, in connection with the current geopolitical situation, the government in 2022 took measures to prevent a shortage of medicines. In particular, the procedure for accelerated registration of drugs has been introduced. In addition, it is possible to purchase drugs from a single supplier.^[2]

Sales of allergy drugs increased in Russia

In 2023, 97.5 million packages of antiallergic drugs were delivered to the Russian market. This is 4.6% more than the previous year. Such data are given in the study, the results of which were published at the end of March 2024. Read more here.

Registration of 550 drugs, 70% of them are domestic

In 2023, approximately 550 drugs were registered in Russia, of which about 70% were domestic products. Such data in mid-March 2024 was published by the Ministry of Health of the Russian Federation. Read more here.

India has become the largest supplier of drugs to Russia

At the end of 2023, India became the largest importer of medicines to Russia. This was announced on March 25, 2024 by RBC with reference to the data of the analytical company RNC Pharma.

In 2023, India was ahead of Germany in terms of the number of deliveries, which had previously led two years in a row. This is due to the fact that European companies are reducing the import of original drugs due to the appearance of analogues and restrictions on work on the Russian market due to the sanctions regime. In 2023, the supply of medicines from Germany decreased by 20% to 238.7 million packages.

India became the largest importer of medicines to Russia

In 2023, the Russian market received 293.9 million packages of drugs from. India This is 3% more than in 2022. Among other large importers of drugs to Russia, it is called - France 149.3 million packages of drugs were imported from it to the Russian market, which is 7.6% more than a year earlier. In addition, large suppliers of drugs are called (Hungary 112.5 million packages of drugs, an increase of 11.6% compared to 2022) and (Belarus 109.8 million packages, 6.9% more than a year earlier). At the same time, deliveries from Great Britain Poland and decreased. So, in 2023, the UK delivered 10.5% less drugs than a year earlier (63.2 million packages), and 16.5% Poland less (60.9 million).

In 2023, Russia opened new markets for the supply of drugs. So, for the first time, medicines were imported from the UAE (35.7 thousand packages), as well as from Armenia (1.6 thousand packages) and Cuba (1.5 thousand). In total, in 2023, 1.8 million packages of foreign medicines entered the Russian market. At the same time, 4.1 billion packages were produced by local companies.

The leader in the supply of drugs among foreign companies was the Indian farm giant Teva, which specializes in the production of generic drugs. In 2023, the company brought 149.8 million packages to Russia. Teva's drug import growth was 11%. In second place in terms of drug delivery to the Russian market is the Indian Dr. Reddy's, which increased imports to Russia by 12% to 110.1 million packages of medicines.^[3]

Drug sales growth by 2% to 2.2 trillion rubles

At the end of 2023, the volume of pharmacy sales of medicines and their shipments in the state segment reached 5.69 billion packages for a total amount of 2.2 trillion rubles, which is 2% more than a year earlier. This was announced in March 2024 by the analytical company AlphaRM.

The volume of sales of drugs in monetary terms in the commercial market amounted to 1.4 trillion rubles. The growth compared to 2022 was 7%. In physical terms, LP sales amounted to 5.07 billion packages, which is 1% less than a year ago.

On average, a person's private spending on medicines in 2023 amounted to 9,827 rubles, which is 6% more than in 2022.

According to information from fiscal data operators, in December 2023, 493 million packages of drugs were sold for 151 billion rubles.

The number of pharmacy outlets in 2023 in the Russian Federation increased by 5% to 777 thousand. Their total revenue rose 7%. The largest pharmacy chain in 2023 was Rigla, which occupies 7.2% of the pharmacy market. The top ten networks also included April, Implosion, Planet Health, Erka & MZ, Neo-Pharm, 36.6, Iris, Vita and Farmland.

The volume of supplies of medicines in the state month for 12 months of 2023 amounted to 622.7 million packages for a total amount of 785.8 billion rubles. In both monetary and physical terms, there is a negative dynamics of 7%. Government spending on drug provision averaged 5366 rubles per person in Russia. This figure reaches its maximum value in the North-West Federal District (6732 rubles), and the minimum - the North Caucasus Federal District (3057 rubles).^[4]

Corvalol sales in Russia decreased to a minimum since 2018

In 2023, 40 million packages of corvalol were sold in Russia, which is 7% less than a year earlier, when citizens purchased about 43 million units. This is evidenced by the data of the marketing agency DSM Group, published on March 1, 2024. Read more here.

The largest pharmaceutical distributors in Russia are named

At the end of 2023, Protek became the largest pharmaceutical distributor in Russia. Its share in direct supplies of medicines (taking into account the budget segment of the industry) amounted to approximately 12.7% in monetary terms. For comparison, a year earlier this figure was 12%. Such data is disclosed on February 14, 2024 by the analytical firm RNC Pharma.

The study says that in 2023, the Russian pharmaceutical market showed positive dynamics: growth compared to the previous year in ruble consumer prices amounted to 4.7%. At the same time, the authors of the report emphasize, the average annual inflation rate was recorded at 6.1%. In the retail segment, the growth of the pharmaceutical market in 2023 reached 7.7%, while the total volume of public procurement decreased by 0.2%.

In second place in the RNC Pharma rating is Pulse with a share of 12.2% versus 12.1% in 2022. Closes the top three "Katren," which on an annualized basis strengthened its position from 11.5% to 11.6%. In addition, the top ten included FC Grand Capital (6.6%), BSS (4.3%), R-Pharm (3.3%), Pharmkomplekt (3.2%), Irvin 2 (2.8%), Medexport (1.8%) and Agroresursy (1.8%).

Analysts note that the multidirectional dynamics in the market sectors in the conditions of a fairly clear specialization of wholesale companies determined the indicators of player development in 2023. A pronounced increase in the share of all companies included in Tor-5 was recorded: in total, it increased by 1.8% over the year. At the same time, the total share of companies from 6th to 25th place was adjusted downward.

The authors of the study indicate that the development of the online direction among pharmaceutical distributors in 2023 entered a period of stagnation. This fact was one of the reasons for the change in investment priorities on the part of most large wholesalers, who focused on expanding the warehouse infrastructure and the development of related, including production competencies.^[5]

Sales of migraine drugs increased in Russia

At the end of 2023, approximately 8 million packages of migraine drugs were sold in Russia. This is 1% more compared to the previous year, when sales were estimated at 7.9 million units. At the same time, in monetary terms, the market volume increased by 10% - from 2.7 billion rubles to 3 billion rubles. Such data are given in the AlphaRM study, the results of which were published on February 7, 2024. Read more here.

Sales growth of anti-inflammatory drugs by 7% to 1.44 trillion rubles

At the end of 2023, the volume of sales of medicines in the retail commercial market in Russia reached 1.44 trillion rubles. This is 7% more than the previous year. In particular, an increase in spending on anti-inflammatory drugs was recorded. At the same time, in physical terms, the volume of sales in annual terms decreased by about 1% - to 5.07 billion packages. Such data are disclosed in the AlphaRM report, published on February 7, 2024.

On average, in the Russian Federation, private expenses for the purchase of drugs per person in 2023 amounted to 9,827 rubles, which is 6% more compared to the previous year. The highest figure was recorded in the North-West Federal District - 11,865 rubles (+ 9% year-on-year), the lowest in the North Caucasus Federal District - 4406 rubles (+ 3% by 2022).

In 2023, the most significant growth in sales among the top 10 therapeutic groups of drugs was demonstrated by anti-inflammatory drugs - plus 15% compared to 2022. Pharmacies sold 259.7 million packages of such drugs for a total amount of about 64.3 billion rubles. The most popular names were nimesulide and ibuprofen with sales of 15.7 billion rubles and 14.3 billion rubles, respectively. The average cost of packaging nimesulide in 2023 amounted to 321.7 rubles (plus 2% year-on-year), ibuprofen - 159.8 rubles (plus 16%).

At the end of 2023, patients spent the most money on angiotensin-converting enzyme (ACE) inhibitors, which are prescribed in the treatment of cardiovascular diseases: 215.8 million packages worth 75.1 billion rubles were sold. In second place are antiprostudal and antitussive drugs with a revenue of 65.2 billion rubles. Drugs for runny nose close the top three with a result of 64.9 billion rubles.

Pharmaceutical Market Analysis, 2023

The growth of drugs produced in Russia to 1483 names

In 2023, the production of 1,483 names of medicines was established in Russia, which is 45 more than a year earlier. The number of brands on the pharmaceutical market during this time increased by 141 positions and reached 2964 items. This is evidenced by the data released on February 1, 2024 by the analytical company RNC Pharma.

According to experts, the development of the assortment in 2023 was almost exclusively due to prescription drugs, the total number of SKUs in the competitive group increased by 502 names. The natural dynamics of the products released in the Rx-category was also higher. Here, relative to 2022, the volume of shipments increased by 3% in packages, while shipments of over-the-counter drugs decreased by 6.2%.

Production of 1,483 names of medicines was established in Russia

For the group of prescription drugs in 2023, the total number of companies shipping drugs to the market amounted to 380 units (28 more than in 2022). And this is despite the suspension of the activities of individual structures, in particular, in 2023, the packaging of a number of GSK vaccines was stopped, which was previously carried out at the SmithKlein Beecham-Biomed site in Petrovo-Dalniy near Moscow. Elpida showed the maximum natural dynamics in 2023: the volume of shipments increased by 15.6 times compared to 2022, we are talking about the supply of the drug of the same name for the treatment of HIV infection.

The second result is demonstrated by Ever Pharma, which last year multiplied the production of Cerebrolysin in partnership with the Russian company Sotex. We also note the NovaMedica company, which last year ensured a 6.1-fold increase in production, the dynamics were provided by the antimigrenous drug Relonova and the sleeping pills Levroso^[6]

Drug production growth by 7.2% to 651 billion rubles

In 2023, Russian pharmaceutical enterprises produced drugs worth 651 billion rubles, which is 7.2% more than a year earlier. This is evidenced by Rosstat data published at the end of January 2024.

According to TASS, citing materials from the department, the production of medicines and materials used for medical purposes increased by 1.9% in 2023. Serums and vaccines in doses for 2023 were produced by 25.5% more than in 2022, and in ampoules their production decreased by 15.5%.

Russian pharmaceutical enterprises produced drugs in the amount of 651 billion rubles

The production of pharmaceutical substances in 2023 decreased by 11.9%. According to Rosstat, dressings and similar products, including those impregnated or coated with medicines, were manufactured in the amount of 665 million packages at the end of 2023, which is 15% higher than a year ago.

According to RNC Pharma estimates, the volume of production of finished medicines in Russia in 2023 amounted to 716.5 billion rubles (in shipping prices of manufacturers, including VAT). Ruble dynamics compared to 2022 was recorded at 7.2%. The natural volume of products produced for the year amounted to 4.09 billion packages, which is 2% less than in 2022.

According to analysts, given the abnormal behavior of consumers and other market participants in the comparison period, even this result can be recognized as positive. Moreover, when conducting calculations in the minimum dosage units (MED), dynamics generally go into a plus. Here, relative to 2022, the increase was recorded at 1.2%. In total, at the end of 2023, pharmaceutical manufacturers localized in Russia shipped more than 80.6 billion MED of finished drugs, calculated in RNC Pharma.^[7]

Reduction of public procurement of drugs by 7% to 864.3 billion rubles

According to the results of 2023, state purchases of drugs in Russia decreased by 7% compared to the previous year and amounted to 864.3 billion rubles. This is evidenced by the data of the analytical company Headway Company, which was exposed on January 24, 2024.

As RBC writes with reference to the calculations of the Headway Company, they include the amounts of contracts for the supply of drugs purchased by state customers of all levels - both federal and regional - for example, to provide therapy to beneficiaries, people with various serious diseases, as well as patients in hospitals.

Confirmed a decrease in government spending on drugs in the analytical company DSM Group. According to their data for January-November 2023, 649.8 billion rubles were spent from the budget for these purposes, which is 23% less than in the same period in 2022. The calculations were made on the basis of auction documentation, Headway Company takes into account all contracts concluded for the year, DSM Group considered purchases upon execution of the contract (for what amount for the period the delivery was carried out).

Experts explain the decrease in public procurement of drugs by the cancellation in 2022 of purchases of drugs for the treatment of coronavirus COVID-19. It is noted that in 2023, the volume of federal purchases that provide medicines, including patients with serious diseases, fell the most,

At the same time, the Ministry of Health of the Russian Federation denies a decrease in the amount of allocated funds for medicines. The department says that in 2023 the volume of purchases increased by 36 billion rubles compared to 2022. They also explained that when assessing, they proceed from the volume of limits of budgetary obligations, and the indicated 36 billion rubles may include contracts concluded in 2022, but deliveries for which were also carried out in 2023.^[8]

Sales of subcutaneous contraceptive implants increased 6 times in Russia

In 2023, pharmacy sales of subcutaneous hormonal contraceptive implants in Russia jumped approximately six times compared to the previous year, reaching 2,670 units. Moreover, these data do not take into account the purchases of private clinics, in which procedures for the installation of such products are most often performed. The corresponding figures are given in a study by the analytical company DSM Group, the results of which were released on December 21, 2023. Read more here.

Sales of foreign pharmaceutical companies in the Russian Federation for six months reached 349 billion rubles despite statements about business cuts

Sales of foreign pharmaceutical companies in the Russian Federation in January-June 2023 reached 349 billion rubles despite their statements about business cuts. This was announced in mid-August 2023 by DSM Group analysts.

According to them, the share of foreign drugs in the Russian market in the first half of 2023 amounted to 34% against 35% a year earlier. In January-June 2021, the indicator was measured at 34%.

According to Vedomosti, referring to the statistics of the DSM Group, except for the "rush" 2022 (then sales of foreign drugs in the first half of the year amounted to 387 billion rubles), recorded in January-June 2023, the indicator became the largest in at least the last six years. For example, in the first half of 2021, it was almost 15% lower - 297 billion rubles.

Experts interviewed by the publication note that many pharmaceutical giants who left our country were replaced by other foreign manufacturers who had not previously been so widely represented on the local market. Also, the promotion of drugs occurs through specialized medical organizations. This is due to the fact that most large foreign companies, including Novo Nordisk and Eli Lilly, reported that they would import medicines into Russia exclusively from the list of vital and necessary. At the same time, most of the income from them falls on public procurement.

DSM Group analysts drew attention to the fact that in Russia sales of drugs taken for weight loss in the first half of 2023 in physical terms increased by 20.3%, to 1.5 million packs, and in money increased by 15.5%, to 4.2 billion rubles year-on-year. According to the company's analysts, Redsin accounts for 44% of the cash sales of such drugs, and Goldline accounts for 33%. Both drugs contain sibutramine, which creates a feeling of false saturation, including in combination with the hypoglycemic agent metformin.^[9]

"Leak" after 3 years again became the largest supplier of drugs

The Protek group of companies, the main owner of which is Russian businessman Vadim Yakunin, in the first quarter of 2023 again became the leading supplier of drugs in Russia. This is stated in the DSM Group study, the results of which were released in early May 2023.

According to the Vedomosti newspaper, Protek's turnover during January-March 2023 amounted to approximately 76.8 billion rubles. against 82.2 billion rubles. in the first quarter of 2022. At the same time, the share of the group of companies in the Russian market on an annualized basis increased from 13% to 13.6%. In second place in the ranking is the distributor Katren, whose revenue for the period under review reached 76.7 billion rubles. This company strengthened its position on an annualized basis from 13.2% to 13.5%. The former leader closes the top three - the Pulse company, whose turnover fell from 90.3 billion rubles. in the first quarter of 2022 to 72 billion rubles. in the first quarter of 2023. The share of this supplier decreased from 14.3% to 12.7%.

The Protek group of companies includes the distributor of CV Leak, the network of clinics, Atlas pharmaceutical companies and Sotex Rafarma, as well as pharmacies, Rigla Be Healthy!, Zhivika And Zdravsiti Pharmacy. It is noted that Protek headed the rating of pharmaceutical distributors in Russia until 2020, but then lost the leadership to Pulse. DSM Group CEO Sergei Shulyak explains the return to the first line of the list by Protek's active participation in public procurement.

The DSM Group report also states that the size of the commercial drug market in Russia in the first quarter of 2023 in ruble terms decreased by 19% compared to the same period in 2022: the volume amounted to approximately 333.9 billion rubles. In total, in three months, the consumption of medicines through pharmacies reached 1.1 billion packages, which is 21.2% less than in the first quarter of 2022.^[10]

2022

Russian manufacturers of cosmetic drugs increased their production by 47.6%

In 2022, 1.39 million packages of cosmetic drugs were produced in Russia, which is 47.6% more than in the previous year. This was reported in the market research agency "GuideMarket" in mid-June 2023. Read more here.

The volume of the pharmaceutical market in Russia increased by 11.9%

The volume of the pharmaceutical market in Russia in 2022 amounted to 2.57 trillion rubles (excluding vaccines against COVID-19), which is 11.9% more than a year earlier. Such data are provided in a report by DSM Group, which was published in early April 2023.

According to researchers, in 2022, the volume of sales of drugs in the Russian Federation in physical terms fell by 6% compared to 2021 and amounted to 5.2 billion packages. For the second year in a row, the market has grown at a double-digit pace. But if before that the growth driver was government purchases of drugs, then in 2022 pharmacy sales grew more strongly, experts say.

In dollars and euros in 2021, the market showed high positive dynamics. In dollar terms, in 2022, the volume amounted to $37.8 billion, which is 21% higher than the year before. In the euro, market dynamics are noticeably higher than + 37%, and the total volume exceeded 36 billion euros.

The share of imported drugs in the market as a whole in 2022 amounted to 55.5% in rubles and 32.3% in packages. The total share of TOP-20 manufacturers in 2022 amounted to 46.8%. The leading positions in 2022 are still occupied by foreign companies Bayer, Novartis and Sanofi. There are six Russian companies in the ranking, while in 2021 there were only four. The public sector occupies 40% of the drug market. In 2022, this figure decreased by 2 percentage points.

The largest increase in purchases of drugs under programs for regional beneficiaries (RLO) in 2022 was 28%. Orphan drugs became the growth driver, they accounted for 64 billion rubles. of the total volume of 183 billion rubles. Part of the purchase of such drugs is transferred to the regional benefit due to a decrease in federal budgets.

The volume of federal benefits was 9% higher than a year earlier. Hospital purchases rose just 1%. The decrease in the incidence of coronavirus infection led to a decrease in tenders for drugs recommended for the treatment of COVID-19. In value terms, the sale of drugs in pharmacies increased by 15% compared to 2021.

Pharmaceutical market of Russia 2022 - DSM Group study

Drug imports increased by 6.2% to 838.9 billion rubles

The volume of supplies of finished medicines to Russia in 2022 increased by 6.2% compared to 2021 and amounted to 838.9 billion rubles (in prices, taking into account the cost of customs clearance, including VAT). Such data were released by RNC Pharma experts in early February 2023.

According to them, in physical terms, the dynamics during calculations in packages are negative - shipments decreased by 8.7%. However, given the sanctions restrictions, sharp fluctuations in demand last year and the generally very high base of 2021, this result itself can be perceived rather positively, the study says.

The total number of countries - manufacturers of finished drugs in 2022 has not changed. Shipments were recorded from 56 regions, but the number of transit directions increased slightly: there were two more of them. In total, last year Russia received GLP from 52 countries. The most noticeable ruble dynamics was characterized by supplies from such regions as Estonia (an increase in ruble volume by 4.8 times) and Turkey (by 2.3 times).

Turkey helped ship a number of Johnson & Johnson drugs to Russia, which went to the company after buying the portfolio of the Indian Unik (Doctor Mom, Rinzasip, Metrogil, etc.). However, local manufacturers were also characterized by an increase in supply volumes, in particular, the Turkish World Medicine multiplied shipments, including through the drugs Artoxan, Kokarnit, etc. The most noticeable reduction in the volume of supplies was recorded in relation to Holland (-32%), and in fact it is completely associated with changes in the supply scheme of Opdivo (BMS). In 2022, it is imported into our country only through Slovenia.^[11]

8.4% increase in drug production

In 2022, drugs worth 608 billion rubles were manufactured in Russia, which is 8.4% more than a year earlier. Such data are given in the statistics of Rosstat (published in early February 2023).

According to the department's calculations, the production of medicines and materials used for medical purposes in 2022 increased by 8.6% compared to 2021. The production of medicines and materials used for medical purposes in 2022 increased by 8.6% compared to 2021. Dressings and similar products, including those impregnated or coated with medicines, were produced 597 million packages in 2022, which is 22.9% more than in 2021.

According to estimates by the consulting company Yakov & Partners, the volume of the Russian pharmaceutical market in 2022 reached 2.8-2.9 trillion rubles, which is 20% more than a year ago, equal to 2.3 trillion rubles. According to the company's estimates, by the end of 2022, 550 Russian and 570 foreign pharmaceutical companies were operating on the domestic market. Despite the lack of explicit restrictions, ten manufacturing companies from "unfriendly countries" have already faced difficulties due to the rupture of supply chains and the political situation in the world, analysts say. At the same time, in 2023 and subsequent years, 95% of the market may be under threat, Yakov and Partners warn, implying import dependence on the Russian pharmaceutical industry.

Most foreign companies have stopped investing in their Russian projects, marketing and promotion, which could subsequently lead to the complete withdrawal of their drugs from the Russian market, Yakov and Partners analysts say. According to their calculations, the share of foreign companies in the Russian market is now about 25% in the budget and 23% in the commercial segments. Collectively, companies from "unfriendly countries" occupy more than half of the drug market, while Russian players account for 36%.^[12]

Foreign pharmaceutical companies stopped supplying only 8% of drugs to Russia

In 2022, only 99 international non-proprietary names (INNs) of drugs ceased to be imported into Russia in 2022, analysts at RNC Pharma calculated. Their data were released in early February 2023.

According to Vedomosti, citing statistics from RNC Pharma, foreign companies have stopped supplying only 8% of the names of drugs to Russia. Among them, in particular, the antiparkinsonic agent levodopa + benserazide, antitumor toremifene and obinutuzumab, as well as the analgesic ibuprofen + codeine (known under the Nurofen Plus brand). True, pharmaceutical companies over the past year continued to ship eight of these 99 INNs in bulk. We are talking, for example, about degludec and aspart insulins from Novo Nordisk and chemotherapy trabectedin from Johnson & Johnson.

The list of drugs whose supplies stopped in 2022 also includes drugs not registered in Russia. They were periodically imported into the country for the treatment of coronavirus infection (COVID-19) or for some other reason, explains Nikolai Bespalov, Development Director of RNC Pharma. As an example, he cites the monoclonal antibody regdanvimab, antitumor agents asparaginase, trifluridine + tipiracil, as well as osilodrostat from Cushing's disease.

According to RNC Pharma, 28 pharmaceutical manufacturers completely stopped deliveries to Russia in 2022. At the same time, in 2022, 30 companies began to import their pharmaceutical products into Russia, of which 7 do it through domestic pharmaceutical manufacturers.

The total volume of drug imports to Russia in 2022 decreased by 9%, amounting to 1.7 billion packages. At the same time, in monetary terms, it grew by 6% - to 838.9 billion rubles. Of the international pharmaceutical companies, the largest volume of drug supplies in physical terms decreased in the Japanese Takeda, which has a plant in Russia.^[13]

State purchases of drugs in Russia increased by 5%

In 2022, the volume of public procurement of drugs in Russia amounted to about 910 billion rubles, which is 5% more than a year earlier. More than half of sales fell on the Central Federal District (472.9 billion rubles). This is evidenced by data from the Headway Company.

As Kommersant writes with reference to this study, in 2022 the Moscow authorities allocated 126.1 billion rubles for these purposes, and 41 billion rubles for the Moscow region. Least of all - 38.6 billion rubles and 25.3 billion rubles - were purchased in the Far East and the North Caucasus, respectively.

The publication notes that purchases of medicines for state medical institutions decreased by 8% year-on-year, to 327.5 billion rubles, against an increase of 20%, to 355.8 billion rubles, in 2021. Analysts recorded the largest drop in purchases in regional clinics - by 32%, city hospitals - by 28%, in regional clinics - by 14%.

Headway Company notes that a significant decline in the hospital segment began in the second half of the year: in July - December 2022, funds were purchased for 150.2 billion rubles, one and a half times less than in the same period in 2021. The level of procurement of drugs by medical institutions in 2022 "did not correspond to the previous ten-year period," Lyudmila Balandina, head of the strategic development department of Headway Company, told the newspaper.

Such dynamics may be due to the fact that in March 2022, operators were allowed to receive advanced funding at the beginning of the year, said Alexey Fedorov, an expert at the All-Russian Union of Patients. DSM Group CEO Sergei Shulyak also agreed with this point of view, indicating that in the spring of 2022 hospitals could be purchased with medicines in advance.

This opinion is also confirmed by the Headway Company data: according to them, in March 2022 alone, medical institutions bought drugs worth 48.4 billion rubles, which is almost 40% more than in 2021.^[14]

Russian pharmaceutical companies increased by 80% the production of new drugs amid the departure of foreign manufacturers from the Russian Federation

In January-July 2022, Russian pharmaceutical companies registered more than 740 new drugs in the country, which exceeds 80% of all registration certificates approved during this period (data from the Ministry of Industry and Trade, published in December 2022). This indicator is due to the departure of foreign manufacturers from the Russian Federation.

According to the National Labeling System, by December 2022, Russian pharmaceutical companies produce more than 1600 drugs with one active ingredient (international non-proprietary name, INN). In total, about 2500 INNs operate on the market, according to DSM Group CEO Sergei Shulyak. Imports are completely replaced by 45 species out of 808 vital and essential drugs.

As Nikolai Bespalov, Development Director of RNC Pharma, explains, foreign pharmaceutical manufacturers have begun to adjust product portfolios amid import substitution. In addition, many refuse individual products or dosage forms if Russian enterprises have begun producing analogues of such drugs.

His words are confirmed by the general director of DSM Group Sergey Shulyak: when Russian analogues appear, it is economically unprofitable to import a foreign drug. Therefore, a number of foreign companies have localized the production of drugs in Russia and are participating in state tenders.

According to RNC Pharma estimates, by the third quarter of 2022, the number of foreign drug brands sold in Russia decreased to 2073 from 2517 by the beginning of 2018. Companies can produce a drug with one active ingredient, but under different brand names. For example, drugs with the active ingredient diclofenac are registered under the brands Voltaren, Veltavel, Flector Rapid, Orthophen, Naklofen, etc.^[15]

Increase in imports of drugs from Switzerland by 40% to $2.3 billion - a record for 30 years

The scale of exports to Russia of non-sanctioned types of Swiss pharmaceuticals products reached its 30-year maximum in 2022.

Concerns and Roche Novartis other Swiss pharmaceutical companies made a profit of 2.1 billion Swiss francs (2.3 billion) through the export of drugs to Russia in 2022 dollars. Sales increased by 40%. Swissinfo

Reduction in drug imports from 27 countries amid conflict in Ukraine

According to the results of 9 months of 2022, Russia has reduced the import of drugs from 27 states - according to the analytical company RNC Pharma. The import of drugs from Cyprus decreased the most against the background of the conflict in Ukraine - by 85% year-on-year. 79% - from Ukraine, 62% - from Canada, imports from Israel fell by 58%, supplies from Germany decreased by 13%.

Due to logistics problems, some foreign companies had to change the supply schemes for their drugs to Russia, that is, to ship, for example, not from European factories, but from Brazil or Puerto Rico. This leads to the fact that in Russia there is a regular shortage of a variety of drugs. At the same time, there is an increase in the supply of products of small companies from Pakistan, Puerto Rico, Argentina, the Czech Republic and Brazil.

The Ministry of Health approved a single operator for the purchase of cancer drugs for federal medical centers

In September 2022, an order was signed by which the Ministry of Health approved a single operator for the purchase of cancer drugs for federal medical centers. It was the Federal Center for the Planning and Organization of Drug Provision of Citizens (FCPILO). Read more here

Named Top 10 most popular prescription drugs in Russia

In early September 2022, the First Electronic Prescription company published the results of a study in which it pointed to the most popular prescription drugs in Russia.

1. "Omeprazole." It is used in the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease and Zollinger-Ellison syndrome. It is also used to prevent upper gastrointestinal bleeding in people at high risk.
2. "Enalapril." The drug is taken for increased heart failure. It is also prescribed more often to women (61%), but the proportion of patients 60 + is higher than that of the first drug - 78
%. 3. "Bisoprolol." It is used for chronic coronary heart disease and arterial hypertension. 77% of patients who received a prescription for it are over 60 years old.
4. "Indapamide." The drug is prescribed to patients diagnosed with hypertension. 78% of patients are over 60, most often the drug is prescribed to women (62%).
5. "Amlodipine." It is taken by people with impaired liver function and in renal failure, in fifth place. 79% of patients who received a prescription for it are over 60 years old.
6. "Lisinopril." This is another drug prescribed to the cores. It is received almost equally by men and women (45% and 55%, respectively), and the age of patients is different.
7. "Diclofenac." This anti-inflammatory drug is prescribed for osteoarthritis, rheumatoid arthritis, or acute chronic ankylosing spondylitis. The medicine is prescribed to patients over 60 years old and women (67%).
8. "Taurine." It is used for treatment of corneal dystrophy, cataracts, corneal injuries. Here again, the maximum of patients over 60 years old (76%), men and women are almost equally.
9. "Atorvastatin." It is a drug capable of lowering plasma cholesterol and lipoprotein concentrations. Most often, it is prescribed to people suffering from diabetes, atherosclerosis or cardiovascular diseases. Most often these are people over 60 years old (82%), both men and women receive it equally often.
10. "Azithromycin." Doctors prescribe it to patients suffering from infectious and inflammatory diseases of the upper respiratory tract, ENT organs (pharyngitis, tonsillitis, sinusitis, otitis media) and lower respiratory tract (acute bronchitis, exacerbation of chronic bronchitis, pneumonia). Here the maximum age range is from 3-7 years (16%) to 70 + (9^[16]

Rosfinmonitoring and the FSB begin to stop the promotion of foreign drugs through doctors

At the end of June 2022, the director Rosfinmonitoring Yuri Chikhanchin , at a meeting with the president Russia Vladimir Putin , said that the department, together FSB with, is working to suppress the activities of foreign pharmaceutical companies to promote their drugs in. According Russia to Chikhanchin, foreign pharmacists use Russian doctors for this purpose.

"Now, together with the FSB, we are working in this direction: foreign pharmaceutical companies, unfortunately, have attracted a number of heads of medical institutions, medical workers in 30 regions... And they pushed their medicines, paying quite a lot of money for it. According to only one scheme, we saw, they handed over 500 million, "said the director of Rosfinmonitoring during a meeting with Vladimir Putin (quoted by the Kremlin website).

At the same time, Yuri Chikhanchin did not cite specific cases as an example. He promised that together with the FSB of Rosfinmonitoring "he will try to figure it out."

'They do it everywhere. They do it both in Europe and overseas too. This is their style of work, "Vladimir Putin reacted.

Criminal cases, as a rule, are initiated over bribes in public procurement of medicines and medical equipment. The defendants in such cases are usually civil servants of regional ministries of health, chief doctors and representatives of distribution companies.

On June 9, 2022, the head of Roszdravnadzor Alla Samoilova reported that the total number of rejected drug series - poor-quality, counterfeit, falsified - decreased four times over the past five years. She noted that by June 2022, each patient can read the QR code and find out where a particular drug was released, where it was sold, trace its entire chain.[17]

Medical institutions obliged to keep records of the consumption of narcotic drugs in a new journal

On March 1, 2022, a decree of the Government of the Russian Federation on new rules for accounting for the consumption of narcotic drugs in Russian medical institutions will enter into force. This became known in mid-February 2022. Read more here.

2021

Sales of weight loss products in Russia for the year increased by 5%

In 2021, sales of weight loss products in Russian pharmacies exceeded 6 billion rubles, which is 5% more than a year ago. Such data in April 2022 were released by AlphaRM analysts.

According to them, there are both medicines and dietary supplements in the pharmacy market for weight loss. In 2021, it was dietary supplements that lost in sales: both in rubles (-8%) and in packages (-6%). Sales of drugs for weight loss, on the contrary, increased: in value terms by 9%, in kind - by 3%.

According to the study, Drugs for weight loss are more expensive, they account for most of the costs of buyers in pharmacies - 4.8 billion rubles in 2021. The value of the dietary supplement market for weight loss is much lower - 1.3 billion rubles. At the same time, the picture in the packages is different - dietary supplements surpass the drug market. In the past year, the dietary supplement market was about 5 million packages against less than 2 million packages of drugs.

The average cost of dietary supplements for weight reduction during the analyzed period was 269 rubles per package. Drugs for these purposes are much more expensive - on average, the buyer paid 2,723 rubles for packaging last year. The price compared to 2020 for dietary supplements decreased by 2%, for medicines increased by 6%.

In 2021, in pharmacies, the maximum costs of buyers in 2021 were for drugs used in obesity: they account for 78.6% of the total market for weight loss products. The rest is occupied by dietary supplements to reduce weight and phytochai.

In physical terms, dietary supplements prevail in the market for weight loss products. For example, phytochai account for 45.5% of all pharmacy sales in packages. Medicines account for only 26.5% of natural consumption.

The leader among drugs in 2021 was the Rededsin brand from Promomed Rus with a market share of 49.7%.^[18]

The largest drug suppliers in Russia

By the end of 2021, Pulse remained the largest suppliers of drugs in Russia, with a turnover of 291 billion rubles, an increase of 14% compared to 2020. The company's share was 14.7%. This was announced in mid-February 2022 by DSM Group analysts.

According to their data, cited by Kommersant, Katren took the second place among pharmaceutical distributors in the Russian Federation, increasing sales by 7.5%, to 257.2 billion rubles and recording a 13 percent market share in the asset. The top three was closed by Protek (revenue - 249.1 billion rubles, an increase of 3.2%).

The fastest growing distributor in the pharmaceutical market in the leading five was R-Pharm"": its turnover in 2021 increased by 51.3%, to 200.7 billion rubles. The company's share was just over 10%. The lion's share of R-Pharm's sales fell on public procurement, because the company specializes in this segment, says DSM Group CEO Sergei Shulyak. R-Pharm is the only one that produces and supplies the drug Artlegia"," which is used, among other things, in case of complications, and the COVID-19 company earned 21 billion rubles on this drug alone, he explained.

The DSM Group drew attention to the beginning of a decrease in the concentration of the Russian market for the supply of drugs in the hands of the largest players. So, if in 2020 the total share of 10 companies increased from 71.4% to 74.1%, then last year the figure decreased to 72.7%. As noted in the DSM Group, the decrease in the share is associated with an increase in the volume of public procurement, as well as with the emergence of new bidders. In general, distributors operating in the public sector demonstrate better results. The average revenue growth of the five largest players in this segment in 2021 was 33%, and in the segment of commercial supplies to pharmacies - about 6%.^[19]

Drug sales in Russian pharmacies decreased by 7.7%, to 4.6 billion packages of drugs

In 2021, 4.6 billion packages of drugs were sold in pharmacies in Russia, which is 7.7% less than a year earlier. Such data in early February 2022 were released by DSM Group analysts.

According to their calculations, the volume of the commercial drug market at the end of 2021 increased by 3.4% on an annualized basis - to 1.17 trillion rubles.

In 2021, the share of original drugs in rubles did not change, but at the same time increased by 0.6% in packages compared to 2020. At the same time, the predominance of the group of generic drugs is significantly - 60.4% in value terms and 81.1% in natural equivalent.

About half of the sales of all generics in 2021 were distributed among three ATC groups - these are "drugs that affect the digestive tract and metabolism" (19.8% share in rubles), "drugs for the treatment of diseases of the nervous system" (15.0%) and "drugs for the treatment of diseases of the cardiovascular system" (14.5%).

To the least extent, generic drugs are presented in the group "antiparasitic drugs, insecticides and repellents" (0.3%). The distribution structure of the original drugs is different. The three most popular ATS groups included "drugs affecting the digestive tract and metabolism" (share of 16.6% in rubles), "drugs for the treatment of diseases of the cardiovascular system" (14.2%) and "drugs for the treatment of diseases of the respiratory system" (11.9%).

The structure of the commercial drug market has changed in favor of expensive drugs. The share of drugs with a price above 500 rubles increased by 3.2% - to 51.3%. 63.9% of the drugs sold in natural units of measurement were produced in Russia, but in view of their low price relative to imported drugs in value terms, they occupied 45.4%.^[20]

The best-selling drugs in Russia

In 2021, Russians most often bought vasoconstrictor drops, medicines for pain and heat, antibiotics, drugs for diseases of the gastrointestinal tract and cardiovascular system. This is evidenced by the data of the Center for the Development of Promising Technologies (CRPT, operator of the Honest Sign digital marking system ).

The first place in terms of sales among drugs in the Russian Federation at the end of 2021 was taken by Xylometazoline nasal drops - they were sold in the amount of 127 million packages worth about 10.4 billion rubles.

Next come citramone (58.4 million packages for 2.1 billion rubles) and ibuprofen (54.6 million packs for 7.2 billion rubles). According to the deputy director of the Center for the Development of Promising Technologies Revaz Yusupov, ibuprofen is popular for its functionality. He both painkillers and lowers the heat. In addition, there is a children's form, which additionally stimulates the sale of the drug.

The list of the most popular drugs in 2021 also includes omeprosol, used, in particular, in the treatment of stomach ulcers (54 million packages worth 2.6 billion rubles were sold in 2021) and ceftriaxone (sales of this antibiotic for the year are estimated at 50 million packages and 2.6 billion rubles).

Analgesics and antipyretics are most widely in demand: in addition to ibuprofen and citramone, paracetamol is a popular remedy, which sold 48.4 million packs for 1.7 billion rubles over the year.

In addition, the list of the best-selling heart drug bisoprolol, the digestive enzyme pancreatin, corvalol and the anti-inflammatory diclofenac.

By the end of 2021, 100% of all drugs produced in civilian circulation have been marked. Almost 90 thousand participants are registered in the drug labeling system, of which 438 are manufacturers, noted Revaz Yusupov.^[21]

Growth of the state segment of the pharmaceutical market for 9 months to 555 billion rubles

The main factor that influenced the growth of the Russian pharmaceutical market in 2020-21 is the COVID-19 pandemic. The pharmo industry showed growth even higher than predicted earlier this year. According to Lancet JSC, the total volume of the state segment of the pharmaceutical market from January to September 2021 amounted to 555 billion rubles, for comparison - in 2020 in the same period the figure was 451 billion rubles.

The Ministry of Industry and Trade presented the state program for the development of the pharmaceutical industry for the next 10 years

In early October 2021, the Ministry of Industry and Trade presented a state program for the development of the Russian pharmaceutical industry for the next 10 years. The document was called "Pharma-2030."

The ministry has set expected development indicators by 2030. According to the strategy, the volume of drug production in Russia should be at least 1.2 trillion rubles a year, the share of locally produced drugs from the general market should be at least 42% in monetary terms, 80% of strategically significant drugs should be localized in Russia before the full production cycle, standard samples should be localized by at least 50%.

It is assumed that the average share of investments in research and development in the industry will be no lower than the global average of 15% in monetary terms. The same should be the share of the revenue of Russian pharmaceutical companies from original drugs, which by 2021 is 5% of the total revenue.

It is planned that domestic drugs in 10 years will account for at least 65% of the total sales of vital and essential drugs, and their availability according to the list of socially significant and especially dangerous diseases will be at least 70%. The volume of exports of Russian pharmaceutical products is supposed to double in constant prices and bring to the level of 30% of domestic production, as well as enter the market of at least 70% of world countries.

For the development of the production of innovative drugs in the Russian Federation, according to the Ministry of Industry and Trade, it is necessary, firstly, to further stimulate the localization of pharmaceutical capacities in the country, primarily focused on the creation of the most common drugs in the Russian Federation. Secondly, amendments to the legislation are needed, which will allow companies to quickly bring innovative drugs to the market, as well as apply for a preferential tax regime for intellectual property and scientific developments.^[22]

"Evalar" leads in sales of dietary supplements

In May 2021, the dietary supplement pharmacy market underwent serious changes in the DSM Group rating of manufacturers compared to the same period in 2020: new companies entered the top 10, eight out of ten leading manufacturers of dietary supplements showed an increase in sales volume.

Traditionally, the leading manufacturer of dietary supplements is Evalar with a share of 16.9% in rubles (the company's sales grew by 5.8%). The growth of the Russian corporation was provided by: a line with various Evalar products (+ 112.5%) and a series of dietary supplements aimed at rejuvenating the body from the inside, Anti-Age (+ 91.4%). At the same time, the greatest decrease was noted by a series of herbal teas "Evalar Bio" (-24.1%), a liver supplement "Ovesol" (-20.5%) and a line of weight loss products "Turboslem" (-19.1%).

The second place is taken by the American manufacturer Solar Vitamin and Herb (market share 7.1% in rubles), in May the company's sales volume decreased by 4.6%.

The third position is occupied by the Canadian manufacturer PharmaMed (market share 5.4% in rubles), the company's sales volume increased by 27.1%. The firm's portfolio includes 9 brands. The increase in sales was more influenced by the implementation of specialized complexes for men's health "SpermActin Forte" (+ 70.4%) and "Men's Formula" (+ 21.9%).

The largest increase in sales of biologically active additives among the top 10 dietary supplement manufacturers in May 2021 was demonstrated by Binnopharm Group (BFG) - 50.3%. In May, immunomodulators (+ 146% in packages), antispasmodics (+ 98% in packages), probiotics (+ 29% in packages) showed a good increase. In general, over the month, Binnopharm Group's retail sales grew by 57% in physical terms, while the market grew in packaging by 15%.

The rise of imports of pharmaceutical products by 74% in January

In January 2021, Russia increased supplies of pharmaceutical products from abroad by 74.7% compared to the same period last year.

2020

The most expensive medicines in Russia

According to the estimates of the analytical agency DSM Group, which were published in November 2021, the most expensive drugs available in Russian pharmacies are (data for 2020):

• domestic drug for psoriasis Efleira (netakimab) from Biocad;
• an analogue of Botox - Dysport from Ipsen;
• osteoporosis drug "Aclasta" (zoledronic acid) Novartis;
• "Vasaprostan" (alprostadil) Amdipharm for erectile dysfunction;
• "Brilinta" (ticagrelor) AstraZeneca for the prevention of stroke and infarction in patients at risk. 

The average cost of packaging such drugs is no more than 16.5 thousand rubles. At the same time, the prices of drugs purchased with funds from the state budget are significantly higher, mainly payment for expensive treatment of cancer, autoimmune and rare hereditary diseases. For example, the cost of the drug for blood cancer "Imbruvik" in Russia is about 385.5 thousand rubles per package.

According to the oncohematologist, whose comment he received, Kommersant accusing the manufacturer of excessive greed is stupid, since bringing a drug of this level to the market requires billions of dollars in costs. Ravil Niyazov, a regulatory specialist at the Center for Scientific Consulting, adds that drugs for rare forms of blood cancer can be compared with orphan drugs: their production and purchases are small, and the costs are comparable to those for drugs produced en masse.

Nikolai Kryuchkov, an expert on the development and research of drugs, claims that the revenue of large pharmaceutical companies is increasing primarily due to the emergence of more expensive drugs and treatment regimens, while the physical consumption of drugs is growing at a more modest pace. According to him, this trend is also characteristic of Russia, where in 2020-2021 the price of drugs increased by 36%, three times ahead of consumer inflation. In addition to the weakening of the ruble, the rise in prices for logistics and raw materials for pharmaceutical production, this is due to the shift in the focus of pharmaceutical companies towards more expensive and technological drugs. Such drugs are more difficult to copy, which means that the copyright holder will be able to remain a monopolist in the market for longer, the expert said.^[23]

Russian pharmaceutical market grew by 10%

The volume of the Russian pharmaceutical market at the end of 2020 reached 2.04 trillion rubles, which is 10% more than a year earlier. Such data from DSM Group analysts were released in early September 2021.

Forbes magazine, using statistics from the DSM Group, compiled a rating of the largest manufacturers of drugs. The first place was taken by R-Pharm, which earned more than other competitors in 2020 - 120.5 billion rubles in revenue and almost 18 billion rubles in profit.

The second place was taken by Biocad, which scored the maximum in the number of permits received for clinical trials. The company's revenue for 2020 amounted to 33.4 billion rubles, profit - 12.2 billion rubles.

The top three pharmaceutical companies in Russia are closed by the research and production company Generium, controlled by the founder of Pharmstandard Viktor Kharitonin. The company received 19.3 billion rubles in revenue and 10.4 billion rubles in profit. Most of the revenue "Generium" earned on sales under the state program of preferential drug provision.

In total, 20 companies from the list increased revenue over the year from 295 billion to 406 billion rubles, profit - from 50.7 billion to 81.5 billion rubles.

The study noted that the state remains the most important source of income for pharmaceutical companies. In 2020, purchases of drugs for medical and preventive institutions, for example, increased by 23.6% and amounted to 401 billion rubles.

The top 20 includes the companies of two more billionaires from the Forbes list: Synthesis (No. 14) Vladimir Yevtushenkov (No. 41, $3.4 billion) and NPO Petrovax Farm (No. 19) Vladimir Potanin (No. 2, $27 billion). Kurgan "Synthesis," which scored a maximum in the number of drugs registered at the enterprise, will participate in the ranking in Binnopharm Group in a year. ^[24]

Sales of medicines increased by 20%, to 1.78 trillion rubles

At the end of 2020, the volume of pharmacy sales of medicines and their supplies in the state segment in Russia amounted to 1.78 trillion rubles, which is 20% more than a year earlier. In physical terms, the market grew by 9% and amounted to 6.52 billion packages. This is evidenced by data from AlphaRM analysts.

Approximately 65% of drug sales in 2020 came from consumer funds. The share of public procurement, respectively, amounted to 35%.

AlphaRM associates the increase in private drug spending with coronavirus (COVID-19) infection. Experts explained the growth in the segment of public procurement primarily by the implementation of the national project on oncological diseases.

Anna Ermolaeva, CEO of AlphaRM, noted that in the pharmacy segment in 2020, Russian drugs were the leaders in sales, albeit with a reservation on the peculiarity of the pandemic period: sales of domestic prescription drugs increased by 32%, over-the-counter - by 34%.

Analysts called the state the main driver of growth in the pharmaceutical market in 2020-2021. Anna Ermolaeva explained that this is due to the expansion of the oncological program and the program of high-cost nosologies from 7 to 14 positions, the start of the cardiology program, an increase in public procurement of an anticoid vaccine and drugs to combat a new coronavirus infection.

Bayer remained the leader of the Russian retail market for medicines in 2020, which accounted for 4.48% of drug sales. The company's revenue grew by 22% on an annualized basis, and drug sales in terms of the number of packages - by 15%.

Novartis retained second place with a 4.14% share and 23% revenue growth. The top three was closed by Otisipharm (share - 3.67%), which rose by five positions over the year due to an increase in revenue by 50%, which was the highest growth rate in the top 10 manufacturers. Next are Stada (3.55%) and Sanofi (3.49%).

If we talk about public procurement of drugs in Russia, then Pharmstandard climbed to the first place from the second in 2020, ahead of the leader of the previous year Novartis. Pharmstandard's revenue from the supply of drugs under state orders in 2020 increased by 35%, and in physical terms, supplies increased by 5%. At the same time, Novartis indicators grew much weaker - by 4% and 10%, respectively.

It is worth noting a 42 percent decrease in sales of drugs in pieces in the state segment at Biocad, while the company's revenue here increased by 17%. Bristol-Myers Squibb had the highest rise in monetary terms - by 55%. In quantitative terms, growth was measured at 36%.

State purchases of drugs in 2020 reached 625 billion rubles, which is 27% more than a year ago. The largest segment is clinical (hospitals, clinics, etc.). Its volume for the year increased by 44%, to 291.8 billion rubles. Preferential drug provision increased by 36.3%, to 226.9 billion rubles, including 114.2 billion rubles under regional subsidies and 44.9 billion rubles under federal ones.

The study says that by the end of 2020 there were 68.6 thousand pharmacies in Russia, of which 29.4 thousand carried out online orders. The latter accounted for 8.5% of sales of pharmacy chains in money and 3.6% in pieces. The rating of sites selling drugs via the Internet is as follows:

• "Аптека.ру" (share in rubles at the end of 2020 - 39.5%);
• Sberbank Eapteka (6.6%);
• "Zdravsiti" (4.3%).^[25]

Sales in pharmacies increased more than government purchases

Contrary to expectations, the commercial segment (pharmacy sales) in rubles grew faster than the public procurement segment. The main driver of steel growth sales of over-the-counter drugs.

The decrease in the market volume in packaging was primarily due to the growth in sales of large packages, while sales in tablets increased in the commercial segment by 1%.

Largest distributors

Top 10 winners of state orders

Cancer patients in Russia doubled their purchases of drugs with their own money

In 2020, drug sales antineoplastic in pharmacies Russia reached 5.2 billion rubles against 4.1 billion and 2.2 billion rubles a year and two years earlier, respectively. Such data are provided in a study prepared by the Pharmaceutical Bulletin industry publication and AlphaRM. More. here

Rosstat: Drug production in Russia increased by 20%, reaching 486 billion rubles

The production of drugs in Russia in 2020 increased by 19.9% compared to 2019 and reached 486 billion rubles. Such data are provided by Rosstat.

According to the department's calculations, the production of medicines and materials used for medical purposes increased by 23% in 2020 compared to the previous year. The annual production of serums and vaccines in ampoules in money increased by 59.2%. In quantitative terms, doses of serums and vaccines were produced by 0.4% less than a year earlier.

By the end of 2020, the production of pharmaceutical substances increased by 17.5% compared to the indicator of one year ago. The production of provitamines, vitamins and their derivatives reached 488 tons (+ 20.6% by 2019), antibiotics - 560 tons (+ 1.7%).

Rosstat also cites data according to which dressings and similar products impregnated or coated with medicines were produced in the amount of 264 million packages in 2020, which is 5.1% less than a year earlier.

According to DSM Group analysts, the pharmaceutical market turned out to be one of the industries that felt the turbulence of 2020 to the greatest extent. Income growth due to the rush demand for medicines, an increase in the role of the public sector, increased activity of regulators and equally active lawmaking - all these factors have become for the industry both strength tests and new opportunities, experts say.

The state segment remains a key driver of the growth of the pharmaceutical market in Russia, and its share of investments has been growing over the past two years. In this regard, the largest buyers of drugs traditionally remain the Ministry of Health of Russia and the Department of Health of Moscow. The rating of the largest drug suppliers also remains stable:

• Pharmstandard;
• R-Pharm;
• Farmimex^[26]

Russians spend billions on cancer drugs with the state allocated 200 billion rubles

According to the IQWIA Research Center, in January-September 2020, Russians spent 2.58 billion rubles on the purchase of cancer drugs. The largest expenses fell on the drug "Methotrexat-Ebewe" - 233.94 million rubles. Read more here.

2019: Russia is a manufacturer of drugs, not medical equipment

In Russia, unlike some other countries, the main share of medical and pharmaceutical production falls on drugs, and not on medical equipment.

2018

The increase in imports of finished drugs to 531 billion rubles (+ 1.1%). Domestic drugs are coming

The emergence of analogues of foreign drugs on the Russian market led to a reduction in imports in 2018. Thus, the import of finished drugs in the Russian Federation amounted to 531 billion rubles, calculated in RNC Pharma. This is only 1.1% more than a year earlier, when the volume of drugs imported into Russia amounted to 525.5 billion rubles, and in 2017, according to last year's data from RNC Pharma, the positive dynamics of imports of finished drugs reached 8.6%^[27].

In physical terms, the volume of deliveries amounted to 1.87 billion packages, 7.7% less than in 2017. The volume of imports of bulk drugs (in-bulk), which amounted to 4 billion minimum dosage units, decreased by 5%. In monetary terms, the dynamics of in-bulk imports turned out to be positive: in 2018, products were imported into the country by 10.3% more than a year earlier. But, according to Nikolai Bespalov, Development Director of RNC Pharma, this is due only to the internal financial processes of companies, and not to changes in relation to pricing policy in Russia.

The maximum import volume, according to RNC Pharma, was shown by the Swiss Novartis in 2018. The company imported products worth 41.6 billion rubles. (taking into account the cost of customs clearance and VAT). The largest positive dynamics of the volume of drugs supplied to Russia from the French Sanofi, which imported 10% more than in 2017.

As follows from the RNC Pharma report, this was also due to the increase in supplies of the drug for the treatment of cardiovascular diseases "Clexane," as well as drugs for therapy in patients with mucopolysaccharidosis of the first type "Aldurazim." Shipments of these drugs increased 2.3 and 3.2 times, respectively. At the end of 2018, the drug Aldurazim (laronidase) entered the Seven High-Cost Nosologies program, one tender for its supply for 625 million rubles. The Ministry of Health has already announced.

Among the companies that, on the contrary, significantly reduced the supply of drugs to Russia, RNC Pharma allocated Israeli Teva, which reduced the volume of imports in monetary terms by 10%. According to analysts, this was due to a 49% reduction in the supply of drugs for the treatment of cardiovascular diseases "Valz," and by 42% - the antiviral drug "Isoprinosine."

In the segment of bulk drugs, the largest volume of imports in physical terms was shown by Sanofi, which imported in-bulk products to Russia for 12 billion rubles. The maximum supply of this company fell on the drug for the treatment of diabetes mellitus "Tujeo-Solostar," as well as on the vaccine "Pentaxim," which is purchased by the Ministry of Health of the Russian Federation within the framework of the National Calendar of Preventive Vaccinations.

According to Nikolai Bespalov, the main reason for the reduction in drug imports is a decrease in the effective demand of the population - in 2018, real incomes of the population decreased. In addition, a large number of generics appear on the Russian market, which supplant original drugs, Mr. Bespalov notes. According to him, including due to the appearance of analogues, a number of foreign companies refused to localize certain names of their drugs in Russia. Among them, according to him, Novartis, Johnson & Johnson, Teva and others.

Israeli Teva announced the localization in Russia of the production of the drug for the treatment of multiple sclerosis "Copaxone" (glatiramer acetate) in 2016 at the facilities of "Nanolek." This drug is the most significant in the company's portfolio: in 2017, its sales on the global market amounted to $3.8 billion. In December 2018, the Russian company Biocad, which registered an analogue of glatiramer acetate, challenged Teva's extended patent for Copaxon at a dosage of 40 mg, having received the opportunity to sell its generic.

Domestic drugs for the therapy of pulmonary diseases showed a 100% increase over the past three years

Between 2015 and 2018, the share of domestic drug supplies for chronic obstructive pulmonary disease (COPD) and bronchial asthma (AD) doubled.

More than 70% or 22.1 million packages of drugs that were treated by Russian patients in 2017 for diseases such as chronic obstructive pulmonary disease (COPD) and bronchial asthma (AD) were produced by the Russian pharmaceutical company Nativa, the British corporation Glaxosmitklein, the German Beringer Ingelheim and the Anglo-Swedish manufacturer Astrasenek.

According to Russian and international clinical standards, combination drugs are used as the basis for the therapy of pulmonary diseases. Over 63% of them are emergency drugs - short-acting beta-agonists (salbutamol, phenoterol, ipratropium bromide + phenoterol). At the same time, the Russian pharmaceutical industry has been producing a new generation of drugs for several years - long-acting bronchodilators and combination drugs (long-acting bronchodilator and inhalation hormone) with the possibility of using it to stop attacks.

Doctors talk about the need to correct the existing bias with excessive use of short-acting beta-agonists, and replace them with effective modern basic therapy drugs, primarily combined drugs and long-acting bronchodilators.

Combination preparations and long-acting bronchodilators are mostly available in a convenient powder form, without restriction on storage temperature. Externally, they look like a portable mini-inhaler, in which a clearly calculated amount of the drug, usually for a 1-2-month course, is extremely easy to use.

Meanwhile, the success of AD and COPD therapy largely depends on the patient's compliance with the recommendations of the attending physician, whether he takes the recommended drugs in the required dosage and multiplicity, as well as how competently the doctor conducts explanatory work with the patient. Up to 74% of patients take drugs incorrectly due to purely technical errors: it is difficult for them to clearly comply with the instructions for using aerosols, where it is necessary to clearly synchronize respiratory forces with the moment of activation of the dosing device, or patients do not breathe deeply before inhalation of drugs in the form of powder, etc. As a result, three out of four patients do not receive an adequate treatment effect - at the same time, the use of modern powder inhalers in combination with the correct explanatory work of the doctor solves this problem.

2017

Leading companies in public procurement

Biocad's share in public procurement of medicines in 2017 amounted to 4.2% with revenue of 15.66 billion rubles, which brought the company to first place in this segment. The top three also included Novartis and Aventis with indicators of 3.5% and 3.2%, respectively. The list is closed by Generium JSC, the second Russian company to be among the ten largest pharmaceutical companies, suppliers of medicines to state medical institutions.

Sales growth in the commercial sector

In January-April 2017, 1,460 million packages were sold in the commercial sector, which is 13.6% more than sales in physical terms for the same period in 2016.

2016: Drug imports to Russia exceed exports by 14 times

Russia can be called a net importer of medicines: imports exceed exports by 14 times.

Almost 80% of imports fall on European countries - primarily Germany and France.

Main export market for Russian medicinal products is the post-Soviet space (86% of total exports).

Structure of imports and exports of drugs in Russia in 2016

The decrease in the volume of the public sector in physical terms in 2016 amounted to 13%, and in general its market share continues to decrease both in monetary and in physical terms.

The growth of the market is ensured by the growth of the commercial segment (+ 8.4% in monetary terms and + 3.4% in physical terms).

Inflation in Russia in 2016 fell to 5.4%, while the rise in prices for drugs amounted to 5% - the lowest figure in three years. Prices for vital drugs due to state regulation are growing much more slowly (+ 1.3%) than for other drugs (+ 6.9%). The volume of the VED market is about half of the total market in physical and monetary terms.

The most significant price increase (+ 7.1%) in 2016 fell on the drugs of the low price segment - cost up to 50 rubles. for packaging. Expensive drugs (with a price above 500 rubles) have risen in price by only 1.9%.

The share of original drugs in monetary terms decreased by 1.3 pp compared to 2015. This suggests that consumers prefer cheaper generic drugs.

The cost of packaging the original drug in 2016 averaged 362 rubles, and generic - 111 rubles.

Over the year, the share of Russian drugs increased by 1.2 pp in value and 1 pp in physical terms.

The sale of Russian drugs in rubles increased by 18%, and imported drugs - only by 6%, so the average cost of packaging a domestic drug was 71 rubles, imported - 253 rubles.

The growth in sales of over-the-counter drugs amounted to + 11% in monetary terms and + 2% in physical terms.

The sale of prescription drugs increased by 7% in monetary terms and by 5.5% in kind.

The larger rise in the cost of over-the-counter drugs is directly related to the rise in drug prices cost up to 50 rubles, since they are 80% represented by over-the-counter drugs.

• Deloitte Report "Trends in the Pharmaceutical Market of Russia - 2017," PDF

2016

The assessment of the capacity of the pharmaceutical market as a whole and its individual elements may vary depending on the source of information. This is due to the fact that different news agencies can use mismatched ways of grouping types of pharmaceutical activities by sector.

According to the results of 2016, Russia ranks 14th in the world in terms of the size of the pharmaceutical market (8th place in 2011). According to the EIU forecast, in 2021 the volume of sales in the country will increase by 31.4%, and Russia will retain 14th place in the ranking.

In 2016, the volume of the Russian pharmaceutical market grew by 6.7% in ruble terms, however, due to the devaluation of the weighted average exchange rate ruble in dollar terms, it decreased by 3%.

Inflation is the main reason for the growth of the pharmaceutical market in monetary terms in 2016.

2015: Sanofi - Sales Leader

2014: Transition to GMP production standards

One of the factors that affects the dynamics of the pharmaceutical market in the Russian Federation in 2014 is the introduction of requirements for mandatory compliance with GMP (Good manufactured practice) production standards with 01.01.2014 (Federal Law "On the Circulation of Medicines" No. 61-FZ). The closure of enterprises that cannot be modernized can lead to a reduction in supply and an increase in prices for domestic medicines.

2013: Imports in physical terms - 40%

The ratio of imported and domestic medicines on the Russian market remained stable during 2011 - 1 half of 2013, and in price terms imported goods occupy about 75% of the market, and in kind - only 40% (since 2011, the shares have slightly shifted in favor of imported goods). This discrepancy is explained by the fact that the average price of imported drugs is several times higher than the prices for medicines produced in the Russian Federation (in June 2013, the average price ratio was 40.6 rubles/185.7 rubles per package).

2012

A state close to stagnation

According to the DSM Group forecast, the Russian pharmaceutical market was supposed to grow by 10% in rubles in 2012 and reach the level of 910 billion rubles.

State policy is aimed at replacing foreign medicines with domestic counterparts. The overwhelming share of the dietary supplement market in the Russian Federation belongs to Russian manufacturers (84% in packages and 67% in value terms in 2012).

The main factors determining the dynamics of the Russian pharmaceutical market are inflationary price increases and a shift in the sales structure towards more expensive products. At the same time, state regulation measures also significantly reduce the profitability of participants in the pharmaceutical market.

Three main groups of participants can be distinguished in the Russian pharmaceutical market:

• pharmaceutical manufacturers (foreign and domestic),
• distributors (wholesale) and
• retail pharmacies (pharmacy chains and individual outlets).

75% of the market is occupied by imported medicines and, accordingly, foreign manufacturers. Russian manufacturers are in the most advantageous position in the case of working with vital and essential drugs (vital and most important drugs), since a premium is recorded to the manufacturer's price (although manufacturers have to register and re-register prices in the event of indexation every year).

Operating profitability at the end of 2012 (many manufacturers are non-public companies and do not disclose their interim results) of the largest Russian manufacturers ranges from 10% to 30%, profit margin before tax - from 5% to 20%.

Russian producers are characterized by a high level of equity - 30-70% (as of the end of 2012). The debt burden indicator is individual for each company. You also need to be careful about intermediate indicators (for all market participants, not only when analyzing the activities of manufacturers), since this industry is still subject to strong seasonal fluctuations.

Almost all major Russian pharmaceutical manufacturers showed revenue growth in 2012, but with a significant spread of indicators (growth from 2 to 48%). The average increase in sales volumes fits into the annual price growth rate (6-7%).

Pharmaceutical distributors ensure the access of foreign manufacturers to the Russian market and the distribution of domestic products. The concentration of the market at the wholesale level is quite high: the 15 largest players account for 78% of the market. The five leaders, as in the situation with manufacturers, are quite stable.

Price restrictions (or rather, markups) on VEDs have seriously affected the activities of pharmaceutical distributors. Since 2010, almost all wholesale companies operate at negative operating profit (loss) and positive profit before tax. This is due to the fact that, faced with the limitation of markups, distributors began to work with buyers and suppliers according to the bonus scheme and reflect bonuses (in fact, operating income and expenses) accrued for receipt and payment as part of non-operational "other" income and expenses. However, even with these additional revenues, profit margin for pre-tax profits remains low (no more than 1% -3%).

Some distributors operate at a net loss through the support of their shareholders and owners. The low profitability of distributors is also manifested in the low concentration of equity. Average indicators rarely exceed 10%, maximum values ​ ​ reach 30%.

Debt burden indicators are also individual for each organization. In addition, it is necessary to take into account the fact that part of the borrowed funds can be obtained from owners and affiliated organizations, that is, in fact, it is the equity of the group. Some large distributors try to "lend" at the expense of their suppliers, delaying payment for the goods. In this case, a large number of lawsuits from counterparties do not necessarily indicate the distress of the company's financial situation, although it makes you think about the ethical aspects of such "business methods." It is worth noting that among large manufacturers such cases are practically not found.

The lower step of the pharmaceutical distribution chain is pharmacy retail chains. This level is characterized by a low degree of market concentration: the 10 largest players account for only 15% of the market. The retail sector has been hit hardest by government controls on drug prices. Almost all large pharmacy chains balance at a break-even point (with operating or net profitability at no higher than 1%) or operate at a loss.

A characteristic feature of pharmacy companies is the presence of a significant debt burden (from 30% to 70% of the total amount of obligations). Moreover, attempts to compare financial debt with any profit indicator do not make much sense due to the actual absence of this profit already at the level of operational result. However, it should also be borne in mind here that part of the borrowed funds can be provided by the owners or other members of the group. Pharmacy chains are actively looking for ways to optimize their activities. In particular, special pharmacies of "low prices" ("discounters") are being created, the range of parapharmaceutical goods is expanding, the prices of which are not subject to state regulation. Nevertheless, the oversaturation of the market with cheap drugs can lead to a decrease in demand and, accordingly, reduce the effectiveness of these measures.

The pharmaceutical market in the Russian Federation is in a state close to stagnation. This nature of market conditions leads to an aggravation of the struggle between its participants, since a significant expansion is possible only due to the share of competitors. A clear trend in the pharmaceutical industry is the formation of vertically integrated holding structures, but this approach is not always effective. In any case, when analyzing the activities of organizations at all levels of the market, one should take into account the influence of the group, both the possible support and the redistribution of financial resources in favor of other affiliated companies.

Ernst & Young Market Participants Survey

In December 2012, Ernst & Young presented the results of its own research on the pharmaceutical market in Russia.

Open the full text of the study, PDF

The reform of the pharmaceutical industry, initiated by the government in 2008, is actively ongoing. 2012 was marked by the adoption of a number of important legislative acts, amendments and correction of the shortcomings of current sectoral legislation. At the same time, the government maintains a course towards the development of the domestic pharmaceutical industry and the support of the Russian manufacturer.

The comments of the study participants received by Ernst & Young showed that they all assess the prospects for the development of the Russian pharmaceutical market at a level above average (3.8 points on a five-point scale). The promised support from the state perhaps gives more confidence to Russian manufacturers: they show more optimism in their forecasts, estimating the market prospects by 4.3 points. Obviously, the confidence of Russian manufacturers in positive the development of the Russian market increased compared to the results of the Ernst & Young study in 2010 (when this figure was 3.8 points).

At the same time, the assessment of the prospects of the industry by foreign producers remained at the same level. According to the results of the survey, the study participants noted an increase in the clarity of the legislative framework. This was undoubtedly facilitated by the refinement of current sectoral legislation, as well as amendments to legislative acts in order to eliminate uncertainties.

2011

The main trend of 2011 can be called the formation of "pharmaceutical clusters." This process takes place as part of the implementation of the Strategy for the Development of the Frame Industry for the period up to 2020. Another significant event in 2011, which will soon affect the pharmaceutical market, was the signing of documents on Russia's accession to the WTO.

Russia in 8th place among the largest pharmaceutical markets in the world

The pharmaceutical market of Russia is one of the ten largest pharmaceutical markets in the world. According to the results 2011 Russia took 8th place. The volume of the Russian pharmaceutical market in 2011 amounted to 824 billion rubles (including VAT) in final consumption prices, which is 12% more than in 2010.

The commercial segment of the Russian market in 2011 shows strong growth indicators (+1%). Sales volume in 2011 in the commercial segment amounted to about 468 billion rubles (16.0 billion dollars). The driver of market growth was inflation (+ 8.8%) and the transition to more expensive drugs.

4.4 billion packages were sold, which is almost the same as in 2010. In 2011, the pharmacy parapharmaceuticals segment did not fully return to the pre-crisis level in terms of growth. The capacity of this segment in 2011 amounted to 130 billion rubles, which is 10% higher than the volume in 2010. Despite this, pharmacies are actively developing this direction in its sales - this is how goods under its own brand are produced primarily according to non-drug positions.

The public sector in 2011 shows growth at 7%. This is one of the most stable segments in the pharmaceutical market. Since its development is due to budget money. On In 2011, 84.7 billion rubles were spent on the purchase of medicines for preferential categories of citizens. The increase compared to 2010 was about 4.7%.

At the end of 2011, the capacity of the hospital procurement segment amounted to 142 billion rubles, which is 9% higher than the 2010 figure. In physical terms, the volume of purchased drugs is about 1 billion packages, which is also 3% higher than in 2010.

The volume of HLS imports to Russia in 2011 amounted to 13.2 billion dollars, which is 11% higher than in 2010.

Largest producers

The Russian pharmaceutical market is importo-oriented. 76% of drugs in monetary terms, which are consumed by the population, are produced abroad. Therefore, the first places in the ranking manufacturers are occupied by foreign companies:

• Sanofi,
• Novartis.
• On the third line is the Pharmstandard only domestic manufacturer in the TOP-20 leading players in the pharmaceutical market. Russia

Distributors

The importance of the wholesale link remains very high due to the geographical characteristics of Russia. Large distributors support a large network of branches and representative offices. Smaller wholesalers are also beginning to create an extensive network of warehouses (for example, FC Pulse, Empire-Pharma). According to the results of 2011, the leaders in the distribution segment are SIA Group (Magnit Pharma) and CV Protek. Their total market share is 33%. Distributors of R-Pharm and BIOTEC are growing rapidly.

Pharmacy chains

2011 for pharmacy chains passed under the sign of "business optimization" in light of the new legislative and tax regulation. The biggest deal of the year is the group's purchase companies A5 and the Hi Capital investment fund of the state pharmacy chain Mosoblfarmatsiya. In as a result, the chain took first place in terms of the number of points (1370 pharmacies). By turnover, the largest networks are:

• «36,6»,
• «Rigla»,
• "Imposia" - their total share reaches 7.2%.

Pharmacy chains in 2011 actively continued to develop the direction of STM ('Private Label').

The second trend was the transition of existing network points to the "discounter" format.

The cost of drugs in Russia

See the main article The cost of drugs in Russia

2018: Price comparison for popular medicines in various regions of the country

Pharmaceutical "Bosnalek" On November 1, 2018, the company announced monitoring the cost of popular over-the-counter drugs in various regions of the country.

The analysis compared the total cost of the conditional "drug basket" out of 10 widely sought-after over-the-counter drugs. Monthly price dynamics were monitored based on data from the research agency IQVIA on the average cost of drugs. Read more here.

How tablets dissolve in the stomach

See also

• Pharmaceutical Global Market

Notes